nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—Thalidomide—leprosy	0.387	1	CrCtD
Pomalidomide—Lenalidomide—Thalidomide—leprosy	0.227	1	CrCrCtD
Pomalidomide—TNF—leprosy	0.141	1	CbGaD
Pomalidomide—CRBN—Thalidomide—leprosy	0.13	0.595	CbGbCtD
Pomalidomide—TNF—Thalidomide—leprosy	0.0541	0.247	CbGbCtD
Pomalidomide—PTGS2—Thalidomide—leprosy	0.0107	0.049	CbGbCtD
Pomalidomide—PTGS2—Dapsone—leprosy	0.00858	0.0392	CbGbCtD
Pomalidomide—CYP1A2—Thalidomide—leprosy	0.00405	0.0185	CbGbCtD
Pomalidomide—CYP1A2—Rifampicin—leprosy	0.00392	0.0179	CbGbCtD
Pomalidomide—ABCB1—Rifampicin—leprosy	0.00343	0.0157	CbGbCtD
Pomalidomide—CYP3A4—Rifampicin—leprosy	0.00206	0.00938	CbGbCtD
Pomalidomide—Pneumocystis jirovecii pneumonia—Thalidomide—leprosy	0.00183	0.0868	CcSEcCtD
Pomalidomide—CYP3A4—Dapsone—leprosy	0.0017	0.00775	CbGbCtD
Pomalidomide—Teratogenicity—Thalidomide—leprosy	0.0011	0.0519	CcSEcCtD
Pomalidomide—Bronchopneumonia—Thalidomide—leprosy	0.00105	0.0498	CcSEcCtD
Pomalidomide—Thromboembolic event—Thalidomide—leprosy	0.000854	0.0404	CcSEcCtD
Pomalidomide—Tumour lysis syndrome—Thalidomide—leprosy	0.000829	0.0392	CcSEcCtD
Pomalidomide—Peripheral sensory neuropathy—Thalidomide—leprosy	0.000805	0.0381	CcSEcCtD
Pomalidomide—Thalidomide—TNF—leprosy	0.000719	1	CrCbGaD
Pomalidomide—Altered state of consciousness—Thalidomide—leprosy	0.000498	0.0236	CcSEcCtD
Pomalidomide—White blood cell count decreased—Thalidomide—leprosy	0.000462	0.0219	CcSEcCtD
Pomalidomide—Embolism venous—Thalidomide—leprosy	0.000456	0.0216	CcSEcCtD
Pomalidomide—Lymphopenia—Thalidomide—leprosy	0.00045	0.0213	CcSEcCtD
Pomalidomide—Platelet count decreased—Thalidomide—leprosy	0.000387	0.0183	CcSEcCtD
Pomalidomide—Febrile neutropenia—Thalidomide—leprosy	0.000382	0.0181	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Thalidomide—leprosy	0.000378	0.0179	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL23R—leprosy	0.000365	0.0879	CbGpPWpGaD
Pomalidomide—Embolism—Thalidomide—leprosy	0.000358	0.0169	CcSEcCtD
Pomalidomide—Hypercalcaemia—Thalidomide—leprosy	0.000331	0.0157	CcSEcCtD
Pomalidomide—Interstitial lung disease—Thalidomide—leprosy	0.000325	0.0154	CcSEcCtD
Pomalidomide—TNF—Canonical NF-kappaB pathway—CYLD—leprosy	0.000292	0.0705	CbGpPWpGaD
Pomalidomide—Nasopharyngitis—Dapsone—leprosy	0.000292	0.0138	CcSEcCtD
Pomalidomide—Muscular weakness—Dapsone—leprosy	0.000288	0.0136	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Thalidomide—leprosy	0.000253	0.012	CcSEcCtD
Pomalidomide—Hypocalcaemia—Thalidomide—leprosy	0.000251	0.0119	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Dapsone—leprosy	0.000246	0.0117	CcSEcCtD
Pomalidomide—Bone pain—Thalidomide—leprosy	0.00024	0.0114	CcSEcCtD
Pomalidomide—Pulmonary embolism—Thalidomide—leprosy	0.00023	0.0109	CcSEcCtD
Pomalidomide—Hyperkalaemia—Thalidomide—leprosy	0.000226	0.0107	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Thalidomide—leprosy	0.000222	0.0105	CcSEcCtD
Pomalidomide—Neuropathy—Thalidomide—leprosy	0.000216	0.0102	CcSEcCtD
Pomalidomide—Sepsis—Thalidomide—leprosy	0.0002	0.00944	CcSEcCtD
Pomalidomide—TNF—Canonical NF-kappaB pathway—RIPK2—leprosy	0.000188	0.0454	CbGpPWpGaD
Pomalidomide—Cardiac failure congestive—Thalidomide—leprosy	0.000184	0.00871	CcSEcCtD
Pomalidomide—Vertigo—Dapsone—leprosy	0.000177	0.00835	CcSEcCtD
Pomalidomide—Atrial fibrillation—Thalidomide—leprosy	0.000176	0.00833	CcSEcCtD
Pomalidomide—Cough—Dapsone—leprosy	0.000171	0.00811	CcSEcCtD
Pomalidomide—TNF—Canonical NF-kappaB pathway—NOD2—leprosy	0.000171	0.0412	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —CYLD—leprosy	0.000168	0.0405	CbGpPWpGaD
Pomalidomide—Hyponatraemia—Thalidomide—leprosy	0.000168	0.00793	CcSEcCtD
Pomalidomide—Pain in extremity—Thalidomide—leprosy	0.000167	0.0079	CcSEcCtD
Pomalidomide—Blood creatinine increased—Thalidomide—leprosy	0.000156	0.0074	CcSEcCtD
Pomalidomide—Dehydration—Thalidomide—leprosy	0.000155	0.00734	CcSEcCtD
Pomalidomide—Dry skin—Thalidomide—leprosy	0.000153	0.00724	CcSEcCtD
Pomalidomide—Hypokalaemia—Thalidomide—leprosy	0.000152	0.00719	CcSEcCtD
Pomalidomide—Breast disorder—Thalidomide—leprosy	0.000151	0.00714	CcSEcCtD
Pomalidomide—Muscular weakness—Thalidomide—leprosy	0.000147	0.00696	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Thalidomide—leprosy	0.000147	0.00696	CcSEcCtD
Pomalidomide—TNF—Apoptosis—LTA—leprosy	0.000147	0.0355	CbGpPWpGaD
Pomalidomide—Insomnia—Dapsone—leprosy	0.000145	0.00686	CcSEcCtD
Pomalidomide—Bronchitis—Thalidomide—leprosy	0.000139	0.00656	CcSEcCtD
Pomalidomide—Pancytopenia—Thalidomide—leprosy	0.000137	0.00648	CcSEcCtD
Pomalidomide—Neutropenia—Thalidomide—leprosy	0.000135	0.00638	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Thalidomide—leprosy	0.000134	0.00634	CcSEcCtD
Pomalidomide—Weight increased—Thalidomide—leprosy	0.000131	0.00621	CcSEcCtD
Pomalidomide—Weight decreased—Thalidomide—leprosy	0.000131	0.00617	CcSEcCtD
Pomalidomide—Hyperglycaemia—Thalidomide—leprosy	0.00013	0.00616	CcSEcCtD
Pomalidomide—Pneumonia—Thalidomide—leprosy	0.000129	0.00612	CcSEcCtD
Pomalidomide—Infestation—Thalidomide—leprosy	0.000129	0.00609	CcSEcCtD
Pomalidomide—Infestation NOS—Thalidomide—leprosy	0.000129	0.00609	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—leprosy	0.000127	0.0306	CbGpPWpGaD
Pomalidomide—Body temperature increased—Dapsone—leprosy	0.000127	0.00599	CcSEcCtD
Pomalidomide—Renal failure—Thalidomide—leprosy	0.000127	0.00598	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Thalidomide—leprosy	0.000126	0.00597	CcSEcCtD
Pomalidomide—Epistaxis—Thalidomide—leprosy	0.000121	0.00574	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—RIPK2—leprosy	0.000116	0.0281	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Thalidomide—leprosy	0.000114	0.0054	CcSEcCtD
Pomalidomide—Oedema peripheral—Thalidomide—leprosy	0.000114	0.00538	CcSEcCtD
Pomalidomide—Urethral disorder—Thalidomide—leprosy	0.000113	0.00536	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000112	0.0271	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Thalidomide—leprosy	0.000107	0.00507	CcSEcCtD
Pomalidomide—Angiopathy—Thalidomide—leprosy	0.000105	0.00496	CcSEcCtD
Pomalidomide—Mediastinal disorder—Thalidomide—leprosy	0.000104	0.00492	CcSEcCtD
Pomalidomide—Chills—Thalidomide—leprosy	0.000104	0.0049	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—HLA-DRB1—leprosy	0.000102	0.0247	CbGpPWpGaD
Pomalidomide—Vomiting—Dapsone—leprosy	0.000102	0.00482	CcSEcCtD
Pomalidomide—Mental disorder—Thalidomide—leprosy	0.000101	0.00479	CcSEcCtD
Pomalidomide—Malnutrition—Thalidomide—leprosy	0.000101	0.00476	CcSEcCtD
Pomalidomide—Headache—Dapsone—leprosy	0.0001	0.00475	CcSEcCtD
Pomalidomide—Back pain—Thalidomide—leprosy	9.73e-05	0.0046	CcSEcCtD
Pomalidomide—Muscle spasms—Thalidomide—leprosy	9.67e-05	0.00457	CcSEcCtD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—RIPK2—leprosy	9.66e-05	0.0233	CbGpPWpGaD
Pomalidomide—Nausea—Dapsone—leprosy	9.53e-05	0.0045	CcSEcCtD
Pomalidomide—Tremor—Thalidomide—leprosy	9.42e-05	0.00446	CcSEcCtD
Pomalidomide—Anaemia—Thalidomide—leprosy	9.3e-05	0.0044	CcSEcCtD
Pomalidomide—Vertigo—Thalidomide—leprosy	9.04e-05	0.00427	CcSEcCtD
Pomalidomide—Leukopenia—Thalidomide—leprosy	9e-05	0.00426	CcSEcCtD
Pomalidomide—Cough—Thalidomide—leprosy	8.78e-05	0.00415	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	8.76e-05	0.0211	CbGpPWpGaD
Pomalidomide—Arthralgia—Thalidomide—leprosy	8.56e-05	0.00405	CcSEcCtD
Pomalidomide—Anxiety—Thalidomide—leprosy	8.53e-05	0.00403	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	8.5e-05	0.00402	CcSEcCtD
Pomalidomide—Confusional state—Thalidomide—leprosy	8.28e-05	0.00391	CcSEcCtD
Pomalidomide—Infection—Thalidomide—leprosy	8.16e-05	0.00386	CcSEcCtD
Pomalidomide—Nervous system disorder—Thalidomide—leprosy	8.05e-05	0.00381	CcSEcCtD
Pomalidomide—Thrombocytopenia—Thalidomide—leprosy	8.04e-05	0.0038	CcSEcCtD
Pomalidomide—Skin disorder—Thalidomide—leprosy	7.97e-05	0.00377	CcSEcCtD
Pomalidomide—Hyperhidrosis—Thalidomide—leprosy	7.94e-05	0.00375	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	7.75e-05	0.0187	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IFNG—leprosy	7.69e-05	0.0186	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Thalidomide—leprosy	7.48e-05	0.00354	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNG—leprosy	7.46e-05	0.018	CbGpPWpGaD
Pomalidomide—Insomnia—Thalidomide—leprosy	7.42e-05	0.00351	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	7.41e-05	0.0179	CbGpPWpGaD
Pomalidomide—Dyspnoea—Thalidomide—leprosy	7.32e-05	0.00346	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—leprosy	7.21e-05	0.0174	CbGpPWpGaD
Pomalidomide—Decreased appetite—Thalidomide—leprosy	7.14e-05	0.00337	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Thalidomide—leprosy	7.09e-05	0.00335	CcSEcCtD
Pomalidomide—Fatigue—Thalidomide—leprosy	7.08e-05	0.00335	CcSEcCtD
Pomalidomide—Pain—Thalidomide—leprosy	7.02e-05	0.00332	CcSEcCtD
Pomalidomide—Constipation—Thalidomide—leprosy	7.02e-05	0.00332	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	6.93e-05	0.0167	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL2—leprosy	6.84e-05	0.0165	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Thalidomide—leprosy	6.76e-05	0.0032	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL2—leprosy	6.63e-05	0.016	CbGpPWpGaD
Pomalidomide—Body temperature increased—Thalidomide—leprosy	6.49e-05	0.00307	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—leprosy	6.14e-05	0.0148	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Thalidomide—leprosy	6.05e-05	0.00286	CcSEcCtD
Pomalidomide—Asthenia—Thalidomide—leprosy	5.89e-05	0.00278	CcSEcCtD
Pomalidomide—Pruritus—Thalidomide—leprosy	5.81e-05	0.00275	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IFNG—leprosy	5.8e-05	0.014	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR2—leprosy	5.72e-05	0.0138	CbGpPWpGaD
Pomalidomide—Diarrhoea—Thalidomide—leprosy	5.62e-05	0.00266	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—leprosy	5.6e-05	0.0135	CbGpPWpGaD
Pomalidomide—Dizziness—Thalidomide—leprosy	5.43e-05	0.00257	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—CD40LG—leprosy	5.38e-05	0.013	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL10—leprosy	5.38e-05	0.013	CbGpPWpGaD
Pomalidomide—Vomiting—Thalidomide—leprosy	5.22e-05	0.00247	CcSEcCtD
Pomalidomide—Rash—Thalidomide—leprosy	5.18e-05	0.00245	CcSEcCtD
Pomalidomide—Dermatitis—Thalidomide—leprosy	5.17e-05	0.00244	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL2—leprosy	5.15e-05	0.0124	CbGpPWpGaD
Pomalidomide—Headache—Thalidomide—leprosy	5.14e-05	0.00243	CcSEcCtD
Pomalidomide—Nausea—Thalidomide—leprosy	4.88e-05	0.00231	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	4.87e-05	0.0118	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	4.8e-05	0.0116	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	4.56e-05	0.011	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—leprosy	4.49e-05	0.0108	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	4.46e-05	0.0108	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	4.36e-05	0.0105	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	4.33e-05	0.0104	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DRB1—leprosy	4.33e-05	0.0104	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—leprosy	4.29e-05	0.0103	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	4.05e-05	0.00977	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—leprosy	3.96e-05	0.00955	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	3.87e-05	0.00934	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—leprosy	3.65e-05	0.00881	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—leprosy	3.65e-05	0.00881	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—leprosy	3.24e-05	0.00783	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—leprosy	3.24e-05	0.00783	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—leprosy	3.16e-05	0.00763	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—leprosy	3.12e-05	0.00753	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—leprosy	2.9e-05	0.007	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	2.82e-05	0.0068	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—leprosy	2.81e-05	0.00678	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	2.51e-05	0.00604	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—leprosy	2.36e-05	0.00569	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—leprosy	2.36e-05	0.00569	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—leprosy	2.29e-05	0.00553	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—leprosy	2.04e-05	0.00492	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	1.95e-05	0.00471	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	1.9e-05	0.00458	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	1.82e-05	0.0044	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—leprosy	1.8e-05	0.00434	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	1.79e-05	0.00433	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	1.71e-05	0.00411	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	1.52e-05	0.00366	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—leprosy	1.42e-05	0.00342	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—leprosy	1.39e-05	0.00334	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—leprosy	1.26e-05	0.00304	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—leprosy	1.23e-05	0.00297	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—leprosy	1.16e-05	0.0028	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	1.1e-05	0.00266	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	1.1e-05	0.00266	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—leprosy	9.18e-06	0.00221	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—leprosy	8.97e-06	0.00216	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	8.27e-06	0.00199	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDHD—leprosy	7.27e-06	0.00175	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC11A1—leprosy	6.52e-06	0.00157	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.25e-06	0.00151	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDHD—leprosy	5.15e-06	0.00124	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.43e-06	0.00107	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDHD—leprosy	4.11e-06	0.000992	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDHD—leprosy	3.17e-06	0.000766	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—leprosy	2.07e-06	0.000499	CbGpPWpGaD
